|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-6-25
|
|
pubmed:abstractText |
We evaluated a novel truncated hygromycin A analog in which the furanose ring was replaced with a 2-fluoro-2-cyclopropylethyl substituent for its activity against multidrug resistant gram-positive bacteria and compared its activity to the activities of linezolid, quinupristin-dalfopristin, and vancomycin. CE-156811 demonstrated robust in vitro activity against gram-positive bacteria that was comparable to that of linezolid.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1098-6596
|
|
pubmed:author |
pubmed-author:BricknerSteven JSJ,
pubmed-author:DuignanJoanJ,
pubmed-author:FineganSteveS,
pubmed-author:GirardDennisD,
pubmed-author:HubandMichael DMD,
pubmed-author:LePhuong TPT,
pubmed-author:MaloneyMeghanM,
pubmed-author:SchaferJohnJ,
pubmed-author:StoneGregory GGG,
pubmed-author:WadeSarah KSK,
pubmed-author:ZaniewskiRichard PRP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2663-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18426902-Acetamides,
pubmed-meshheading:18426902-Anti-Bacterial Agents,
pubmed-meshheading:18426902-Cinnamates,
pubmed-meshheading:18426902-Dioxoles,
pubmed-meshheading:18426902-Drug Resistance, Multiple, Bacterial,
pubmed-meshheading:18426902-Gram-Negative Bacteria,
pubmed-meshheading:18426902-Gram-Positive Bacteria,
pubmed-meshheading:18426902-Humans,
pubmed-meshheading:18426902-Hygromycin B,
pubmed-meshheading:18426902-Microbial Sensitivity Tests,
pubmed-meshheading:18426902-Molecular Structure,
pubmed-meshheading:18426902-Oxazolidinones
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
|
|
pubmed:affiliation |
Pfizer Global Research & Development, Groton/New London Laboratories, Pfizer Inc., Groton, Connecticut 06340, USA. gregory.stone@astrazeneca.com
|
|
pubmed:publicationType |
Journal Article,
In Vitro
|
